Chaime Orlev
Director of Finance/CFO at KAMADA LTD.
Net worth: 61 836 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Tsur | M | 73 | 34 years | |
Leon Recanati | M | 76 | 19 years | |
Lilach Asher Topilsky | F | 54 | 5 years | |
Nir Livneh | M | 45 | 10 years | |
Menachem Atzmon | M | 79 | 25 years | |
Lilach Payorski | F | 51 | 3 years | |
Hanni Neheman | F | 54 | 10 years | |
Karnit Goldwasser | F | 47 | 5 years | |
Amir London | M | 55 | 11 years | |
Ishay Davidi | M | 62 | 5 years | |
Uri Botzer | M | - | 2 years | |
Orit Pinchuk | F | 59 | 10 years | |
Liron Reshef | M | - | 1 years | |
Eran Nir | M | 51 | 8 years | |
Naveh Tov | M | 60 | 8 years | |
Benjamin Dekel | M | - | 1 years | |
Boris Gorelik | M | - | 4 years | |
Assaf Itshayek | M | 52 | 1 years | |
Ethel M. Koczon | F | - | 9 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mark J. Fitzpatrick | M | 61 | 6 years | |
Colin Foster | M | 61 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 2 years |
Udi Gilboa | M | 57 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 5 years |
Mark Leuchtenberger | M | 67 | 1 years | |
Samuel Rubinstein | M | 59 | 2 years | |
Dror Brandwein | M | - | 3 years | |
Drew Enamait | M | 50 | 6 years | |
Tara Mccarthy | F | 50 | - | |
Ruth Wolfson | M | 77 | 14 years | |
Itzhak Krinsky | M | 71 | 2 years | |
Avraham Berger | M | 72 | 5 years | |
Amiram Boehm | M | 52 | - | |
Jason Fredette | M | - | 1 years | |
Gili Cohen | M | 57 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 3 years |
Gil Efron | M | 57 | 6 years | |
Harold Jacob | M | 69 | - | |
John Scarlett | M | 73 | 6 years | |
David Stack | M | 72 | 7 years | |
Michael Berelowitz | M | 79 | 4 years | |
Steven Katz | M | 76 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
Alex Werber | M | 71 | - | |
Vincent J. Miles | M | 73 | 3 years | |
Yifat Philip | F | 47 | 3 years | |
Robert Friedman | M | 68 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 2 years |
Asaf Yosef Frumerman | M | 39 | 2 years | |
Ari Shamiss | M | 65 | - | |
Avri Havron | M | 76 | 8 years | |
James Tobin | M | 79 | 1 years | |
Gwen Melincoff | M | 72 | 1 years | |
John Thero | M | 63 | 6 years | |
Ansbert Gadicke | M | 66 | 2 years | |
Oren Elmaliah | M | 40 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
Roy Eldor | M | - | - | |
David Caron | M | - | - | |
Hanan Samet | M | 54 | 3 years | |
Ralf H. Rosskamp | M | 71 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 1 years |
Anand Varadan | M | 57 | 1 years | |
Michal Ayalon | M | 57 | 3 years | |
Michal Stein | M | - | 3 years | |
Ido Morpurgo | M | 51 | 4 years | |
William Ludlam | M | 59 | 6 years | |
Efrat Makov | F | 56 | 1 years | |
Asi Haviv | M | - | 9 years | |
Patrick Schnegelsberg | M | 60 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
Vered Caplan | F | 55 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 3 years |
Jean-Pierre Elisha Martinez | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
Gutman Lior Soussan | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 1 years |
David M. DeMedio | M | 52 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 1 years |
Albert Passner | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
Fredric D. Price | M | 78 | 5 years | |
Gary Patou | M | 65 | 6 years | |
Jack Eitan Kyiet | M | 55 | 1 years | |
Ehud Arbit | M | - | - | |
George Drazenovic | M | 53 | - | |
Josef Neuhaus | M | 60 |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | 2 years |
Shmuel Levi | M | - |
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | - |
Colleen Wilson | F | 47 | - | |
Liliana Bar | M | 68 | 7 years | |
Lior Fhima | M | - | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 51 | 65.38% |
United States | 25 | 32.05% |
Netherlands | 2 | 2.56% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chaime Orlev
- Personal Network